Citations

Clear

862 citation(s) found for "Habermann, EB".

Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma
Witzig, Thomas E. , Zinzani, Pier Luigi , Tuscano, Joseph M. , Drach, Johannes, Ramchandren, Radhakrishnan , Beşışık, Sevgi Kalayoğlu , Takeshita, Kenichi , Bravo, Marie‐Laure Casadebaig, Zhang, Lei , Witzig, T.E. , Habermann, Thomas M. , Fu, Tommy , Goy, Andre Henri , Zinzani, Pier Luigi

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 10 | Pages: No page available

10.1002/ajh.24854 | PMID 28699256 Get It

AbstractMantle cell lymphoma (MCL) is a type of non‐Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post‐bortezomib). The purpose of this report is to provide longer follow‐up on the MCL‐001 study (follow‐ups were 6.8 [NHL‐002], 7.6 [NHL‐003], and 52.2 [MCL‐001] months). The 206 relapsed MCL patients treated with single‐agent lenalidomide (25 mg/day PO, days 1 to 21 every 28‐days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow‐up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%‐29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single‐agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.
Risk of cutaneous T‐cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non‐Hodgkin lymphoma
Chang, Timothy W., Weaver, Amy L. , Wriston, Cooper C., Call, Timothy G. , Brewer, Jerry D., Shanafelt, Tait D. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

International Journal of Dermatology | July 7, 2017 | Volume: 56 | Issue: 11 | Pages: 1125-1129

10.1111/ijd.13653 | PMID 28685851 Get It

AbstractBackgroundSecond hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy‐related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B‐cell lymphoma. Although cutaneous T‐cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non‐Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program.MethodsWe searched the SEER 13 registries for patients with a diagnosis of CLL and NHL between 1992 and 2008. Among patients identified, we evaluated the incidence of CTCL.ResultsAmong 31,286 patients with CLL, the incidence of CTCL was not significantly higher in men than women: 104.2 (95% CI, 50.0–191.8) and 28.1 (95% CI, 3.4–101.3) per 1,000,000 person‐years, respectively (P = 0.06). Among 97,691 patients with NHL, the incidence of CTCL was similar in men and women (97.9 [95% CI, 62.0–146.9] and 92.0 [95% CI, 56.2–142.1] per 1,000,000 person‐years, respectively; P = 0.84). The incidence of CTCL among males with CLL (standardized incidence ratio [SIR], 3.0 [95% CI, 1.4–5.5]), males with NHL (SIR, 3.7 [95% CI, 2.3–5.5]), and females with NHL (SIR, 5.9 [95% CI, 3.6–9.1]) was significantly higher than expected in the general population (all P < 0.001).ConclusionThe risk of CTCL is greater in men with CLL than in the general population. In patients with NHL, both men and women are at greater risk for CTCL than in the general population.
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy
Farooq, Umar , Maurer, Matthew J. , Thompson, Carrie A. , Thanarajasingam, Gita , Inwards, David J. , Micallef, Ivana N. , Macon, William R. , Syrbu, Sergei , Lin, Tasha , Lin, Yi , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Link, Brian K. , Micallef, Ivana, Macon, William, Farooq, Umar , Habermann, Thomas M. , Cerhan, James R. , Maurer, Matthew , Link, Brian K , Lin, Yi , Syrbu, Sergei

Mayo Clinic

British Journal of Haematology | June 27, 2017 | Volume: 179 | Issue: 1 | Pages: 50-60

10.1111/bjh.14813 | PMID 28653407 Get It

Summary This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma ( DLBCL ) after failure of front line anthracycline‐based immunochemotherapy ( IC ). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource ( MER ) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B‐cell lymphoma ( PMBL ) patients treated with front‐line anthracycline‐based IC were followed for relapse. Patients with relapse on follow‐up and subsequently retreated were included in this analysis. 1039 patients received anthracycline‐based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years ( OS 4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (auto HCT ) with OS 4 from auto HCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS 4 of 47% but those with a transient or no response to initial therapy had OS 4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo auto HCT . The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL .
Thirty-day postoperative morbidity and mortality after temporal lobectomy for medically refractory epilepsy
Kerezoudis, Panagiotis , McCutcheon, Brandon A., Murphy, Meghan E. , Rajjoub, Kenan , Ubl, Daniel S. , Habermann, Elizabeth B. , Bydon, Mohamad , McCutcheon, Brandon, Ubl, Daniel, Worrell, Gregory A. , Gompel, Jamie J. Van , Habermann, Elizabeth

Mayo Clinic

Journal of Neurosurgery | June 23, 2017 | Volume: 128 | Issue: 4 | Pages: 1158-1164

10.3171/2016.12.jns162096 | PMID 28644097 Get It

OBJECTIVETemporal lobectomy is a well-established treatment modality for the management of medically refractory epilepsy in appropriately selected patients. The aim of this study was to assess 30-day morbidity and mortality after temporal lobectomy in cases registered in a national database.METHODSA retrospective cohort analysis was conducted using a multiinstitutional surgical registry compiled between 2006 and 2014. The authors identified patients who underwent anterior temporal lobectomy and/or amygdalohippocampectomy for a primary diagnosis of intractable epilepsy. Univariate and multivariable analyses with regard to patient demographics, comorbidities, operative characteristics, and 30-day outcomes were applied.RESULTSA total of 216 patients were included in the study. The median age was 38 years and 46% of patients were male. The median length of stay was 3 days and the 30-day mortality rate was 1.4%. Fourteen patients (6.5%) developed at least one major complication. Return to the operating room was observed in 7 patients (3.2%). Readmission within 30 days and discharge to a location other than home were available for 2011–2014 (n = 155) and occurred in 11% and 10.3% of patients, respectively. Multivariable regression analysis revealed that increasing age was an independent predictor of discharge disposition other than home and that male sex was a significant risk factor for the development of a major complication. Interestingly, the presence of the attending neurosurgeon and a resident during the procedure was significantly associated with decreased odds of prolonged length of stay (i.e., > 75th percentile [5 days]) and discharge to a location other than home.CONCLUSIONSUsing a multiinstitutional surgical registry, 30-day outcome data after temporal lobectomy for medically intractable epilepsy demonstrates a mortality rate of 1.4%, a major complication rate of 6.5%, and a readmission rate of 11%. Temporal lobectomy is an extremely effective therapy for seizures originating there—however, surgical intervention must be weighed against its morbidity and mortality outcomes.
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
Link, Brian K. , Syrbu, Sergei , Thompson, Carrie A. , Farooq, Umar , Novak, Anne J. , Allmer, Cristine, Lunde, Julianne J. , Macon, William R. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Weiner, George J. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Farooq, Umar , Slager, Susan L. , Kay, Neil E. , Witzig, Thomas E. , Link, Brian K , Weiner, George , Syrbu, Sergei

Mayo Clinic

International Journal of Epidemiology | June 12, 2017 | Volume: 46 | Issue: 6 | Pages: 1753-1754i

10.1093/ije/dyx119 | PMID 29025017 Get It

Analysis of Postoperative Venous Thromboembolism in Patients With Chronic Ulcerative Colitis: Is It the Disease or the Operation?
McKenna, Nicholas P. , Ubl, Daniel S. , Glasgow, Amy E. , Mathis, Kellie L. , Pembérton, John H., Habermann, Elizabeth B. , Glasgow, Amy E. , Behm, Kevin T. , Cima, Robert R. , Habermann, Elizabeth , McKenna, Nicholas P , Glasgow, Amy E

Mayo Clinic

Diseases of the Colon & Rectum | June 8, 2017 | Volume: 60 | Issue: 7 | Pages: 714-722

10.1097/dcr.0000000000000846 | PMID 28594721 Get It

BACKGROUND: Patients with IBD have a higher baseline risk of venous thromboembolism, which further increases with surgery. Therefore, extended venous thromboembolism chemoprophylaxis has been suggested in certain high-risk cohorts. OBJECTIVE: The purpose of this study was to determine whether the underlying diagnosis, operative procedure, or both influence the incidence of postoperative venous thromboembolism. DESIGN: This was a retrospective review. SETTINGS: The American College of Surgeons–National Surgical Quality Improvement Project database was analyzed. PATIENTS: The NSQIP database was queried for patients with chronic ulcerative colitis and non-IBD undergoing colorectal resections using surgical Current Procedural Terminology codes modeled after the 3 stages used for the surgical management of chronic ulcerative colitis from 2005 to 2013. MAIN OUTCOME MEASURES: We measured 30-day postoperative venous thromboembolism risk in patients with chronic ulcerative colitis based on operative stage and risk factors for development of venous thromboembolism. RESULTS: A total of 18,833 patients met inclusion criteria, with an overall rate of venous thromboembolism of 3.8. Among procedure risk groups, venous thromboembolism rates were high risk, 4.4%; intermediate risk, 1.6%; and low risk, 0.7% (across risk groups, p < 0.01). Emergent case subjects exhibited a higher rate of venous thromboembolism than their elective counterparts (6.9% vs 3.1%). Factors significantly associated with venous thromboembolism on adjusted analysis included emergent risk case (adjusted OR = 7.85), high-risk elective case (adjusted OR = 5.07), intermediate-risk elective case (adjusted OR = 2.69), steroid use (adjusted OR = 1.54), and preoperative albumin <3.5 g/dL (adjusted OR = 1.45). LIMITATIONS: Because of its retrospective nature, correlation between procedures and venous thromboembolism risk can be demonstrated, but causation cannot be proven. In addition, data on inpatient and extended venous thromboembolism prophylaxis use are not available. CONCLUSIONS: Emergent status and operative procedure are the 2 highest risk factors for postoperative venous thromboembolism. Extended venous thromboembolism prophylaxis might be appropriate for patients undergoing these high-risk procedures or any emergent colorectal procedures. See Video Abstract at http://links.lww.com/DCR/A339.
BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE)
Thanarajasingam, Gita , Novotny, Paul J. , Nowakowski, Grzegorz S. , Flowers, Christopher R. , Blum, Kristie A. , Pitcher, Brandelyn N., Atherton, Pamela J. , Tan, Angelina D., Sloan, Jeff A. , Leonard, John P. , Dueck, Amylou C. , Witzig, Thomas E. , Habermann, Thomas M. , Bartlett, Nancy L. , Jung, Sin‐Ho

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 213-215

10.1002/hon.2438_78 Get It

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES
Wang, Y., Wang, S.S., Inwards, David J. , Rothman, Nathaniel , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Witzig, Thomas E. , Cozen, Wendy , Morton, Lindsay M. , Chanock, Stephen Jacob , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4 Get It

GB VIRUS‐C (GBV‐C) INFECTION AND RISK OF LYMPHOMA: A CASE‐CONTROL STUDY FROM NORTH AMERICA
Allmer, Cristine, Xiang, Jinhua , Klinzman, Donna, Feldman, Anya, Nowakowski, Grzegorz S. , Liebow, Mark , Larson, Matthew , Call, Timothy G. , Famà, Angelo , Link, Brian K. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Stapleton, Jack T.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 55-56

10.1002/hon.2437_40 Get It

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
Ghesquières, Hervé , Nicolas‐Virelizier, Emmanuelle , Thompson, C., Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Steven M., Sarkozy, Clémentine , Link, Brian K. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 34-35

10.1002/hon.2437_15 Get It